What is the therapeutic window?
What does oncogene dependence mean?
Bypass resistance changes the drug binding pocket so the inhibitor no longer grips.
Circle one: True False
The original target stays suppressed but a parallel receptor is now active. What is it?
Relapse sequencing shows a fresh pocket mutation, and pathway output stays high. What do you conclude?
Why does relapse often arrive faster than mutation rates predict?
How do you design for lasting control given pre-existing clones?
A colleague blames every relapse on poor dosing. What better hypothesis do you test first?